Under-occupied developments in China

Correcting and Enhancing the Global Understanding of the Role of Condoms in Reproductive Health — the Chinese Approach

Retrieved on: 
Tuesday, October 24, 2023
Survival, Birth, General assembly, AIDS, Reproductive Health Supplies Coalition, Wuhan Institute of Virology, Incidence, Health, Fertility, Life, LaTeX, HIV, Intellectual property, Gynaecology, Research, R, Condom, Public opinion, Ministry, Development, Speech, Male, RHSC, Chinese Academy of Sciences, Pregnancy, Social responsibility, Academic Model Providing Access to Healthcare (AMPATH), HBM, Safety, Under-occupied developments in China, Vertically transmitted infection, Infertility, Role, Infection, Abner Genece, Birth control, Virology

First -- Sexually transmitted diseases such as AIDS have caused great damage to the reproductive system, seriously threatening life and health. 

Key Points: 
  • This conference was jointly hosted by the Reproductive Health Supplies Coalition (RHSC) and the Ministry of Health of Ghana.
  • He was invited to attend the conference and delivered a keynote speech titled "Correcting and Enhancing the Global Understanding of the Role of Condoms in Reproductive Health — the Chinese Approach.
  • And continue to carry out innovative research and development in the global reproductive health field, and contribute to the Chinese plan to improve the global reproductive health level.
  • The company is committed to addressing the root causes of reproductive health issues in China and even around the world, correcting and enhancing the world's new understanding of condoms in terms of reproductive health and safety.

Viva Biotech Attended SAPA-China

Retrieved on: 
Thursday, April 13, 2023
Medicinal chemistry, Science, Intellectual property, SAPA, MOA, Senior, Exhibition, ASMS, SPR, Challenge, Under-occupied developments in China, Development, Journal, Patient, PCSK9, Conference, Synthetic biology, Fine chemical

Viva Biotech was invited to participate in this annual conference, and Dr. Jianhua Cai, Senior Vice President of Viva Biotech, and Dr. Jianguo Ma, Senior Vice President of Viva Biotech and CEO of Langhua Pharmaceutical, were invited as guest speakers in the keynote speeches.

Key Points: 
  • Viva Biotech was invited to participate in this annual conference, and Dr. Jianhua Cai, Senior Vice President of Viva Biotech, and Dr. Jianguo Ma, Senior Vice President of Viva Biotech and CEO of Langhua Pharmaceutical, were invited as guest speakers in the keynote speeches.
  • As one of the key players in innovative drug discovery CRO, Viva has served thousands of global innovative drug development clients in the past decade.
  • He believes that in the future, Viva Biotech can empower more domestic innovative drug companies and help them achieve internationalization in original drug research.
  • At SAPA-CHINA, Viva Biotech fully demonstrated its one-stop platform for early-stage structure-based drug discovery to commercial drug delivery, as well as multiple core technologies and successful cases such as protein production and preparation, structural biology, cryo-EM, drug screening, Bioassay, medicinal chemistry, computer-aided drug design, etc.

KraneShares Launches China Innovation ETF Targeting Growth Sectors and Private Companies

Retrieved on: 
Thursday, October 7, 2021
Spend, Steps, China International Capital Corporation, Ticker, Investment, Internet, United Nations, Electricity, LLC, Turnkey asset management program, Development, US, CNNIC, Time, Renewable energy, Star Market, United States Chamber of Commerce, ETF, China Power Clean Energy Development, Tamaulipas, Principles for Responsible Investment, Contract, UN, The New York Times, Statista, Solution, Government, Risk, Prospectus, Semiconductor, KGRN, Statistics, Least, Bloomberg, Funding, Fund, KSTR, KGRO, Responsibility, CICC, IPO, KURE, MSCI, Localization protected quantum order, Industry, SSE, Financial adviser, SIDCO, Under-occupied developments in China, CEO, Commerce, Lithium, Life insurance, Bank, Security (finance)

NEW YORK, Oct. 7, 2021 /PRNewswire/ -- Krane Funds Advisors, LLC ("KraneShares"), a global asset manager known for its China-focused exchange-traded funds (ETFs) and innovative China investment strategies, today announced the launch of the KraneShares China Innovation ETF (Ticker: KGRO) .

Key Points: 
  • NEW YORK, Oct. 7, 2021 /PRNewswire/ -- Krane Funds Advisors, LLC ("KraneShares"), a global asset manager known for its China-focused exchange-traded funds (ETFs) and innovative China investment strategies, today announced the launch of the KraneShares China Innovation ETF (Ticker: KGRO) .
  • KGRO is an active ETF that provides investors with core exposure to the brightest high-growth areas within China's economy by combining "New China" sectors.
  • KGRO primarily invests in the following KraneShares ETFs:
    KraneShares CSI China Internet ETF (Ticker: KWEB )
    KraneShares MSCI All China Health Care Index ETF (Ticker: KURE )
    KraneShares MSCI China Clean Technology Index ETF (Ticker: KGRN )
    KraneShares CICC China 5G & Semiconductor ETF (Ticker: KFVG )
    KraneShares SSE STAR Market 50 Index ETF (Ticker: KSTR )
    KGRO may also invest up to 15% of its net assets in the securities of private companies that align with these themes or appear to be attractive opportunities, including companies preparing for an initial public offering.
  • "KGRO provides investors with a model portfolio of our ETFs representing what we believe to be the top growth opportunities in China, in a single ETF."